Melanoma

TAP-1 technology corroborated in models of skin cancer

Published in Vaccine Weekly, June 9th, 2004

GeneMax Corp. (GMXX) announced its patented TAP-1 (transporters associated with antigen processing) anticancer technology is effective in generating immune responses against melanoma in mice.

A recent article in the Journal of Immunology corroborates GeneMax's TAP-1 technology promotes an immune response that destroys these cancer cells.

In this study, two vaccine approaches (adenovirus and dendritic cell-based) were tested for their efficacy against melanoma (skin cancer) cells. Experiments with both tumor vaccines demonstrated that introduction of TAP-1 to the melanoma cells increased the recognition and destruction of the cancer cells by...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-06-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry